Pelthos Therapeutics Inc（PTHS）财务数据PTHSPelthos Therapeutics Inc

Pelthos Therapeutics Inc (PTHS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial operations, accounting for 98.8% of total sales, equivalent to $15.42M. Another important revenue stream is Research and Development operations. Understanding this composition is critical for investors evaluating how PTHS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Pelthos Therapeutics Inc maintains a gross margin of 70.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -111.02%, while the net margin is -150.08%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PTHS converts its operational activities into shareholder value.

In the context of the broader market, PTHS competes directly with industry leaders such as NSRX and EDSA. With a market capitalization of $36.42M, it holds a leading position in the sector. When comparing efficiency, PTHS's gross margin of 70.18% stands against NSRX's N/A and EDSA's N/A. Such benchmarking helps identify whether Pelthos Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Pelthos reported a revenue of $15.6 million in Q2 2026, but it has a history of significant net losses, including $23.4 million in Q2 2026. The gross margin is relatively strong at 70.18%, indicating potential profitability if revenues increase.